BridgeMD
New treatment option for Vitiligo
Official title Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus
ClinicalTrials.gov ID: NCT06719024
What this study is testing
What is Ruxolitinib Cream 1.5%?
Ruxolitinib Cream 1.5% is an investigational medicine, given as an once-daily treatment applied to the skin, being studied as a potential treatment for vitiligo.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This trial is a prospective, open-label, single-center, split face randomized controlled study comparing 1.5% topical Ruxolitinib cream twice daily (BD) to aqueous cream in treating non-segmental vitiligo (NSV) of the face and neck in patient previous failed to respond to topical tacrolimus 0.1%. Aqueous cream twice daily application will be used as control group treatment.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 85
You may be able to join if
- 18 - 85 year old
- Have a clinical diagnosis of stable non-segmental vitiligo
- Depigmentation including at least 0.5% of the BSA on the face and neck
- Previously treated with topical tacrolimus 0.1% BD for at least 3 months without significant response
- Agree to stop using any topical treatments on face and neck and systemic treatment for vitiligo during the washout period until the trial concludes...
You likely can't join if
- Patients who refuse to give consent
- Presence of different vitiligo types or other skin depigmentation conditions like piebaldism or leprosy, etc.
- History of using depigmentation treatments other than hydroquinone for vitiligo or pigmentation issues
- Any skin condition affecting study participation, active skin infections one week before the study starts, issues impacting vitiligo evaluation, or...
- Significant medical disease that may hinder use of topical JAK inhibitor, e.g. serious infection, untreated chronic hepatitis, malignancy within 5...
- Specific treatment use within certain periods before starting (Baseline visit): 1 week for topical vitiligo treatments 4 weeks for immunomodulators...
See the full eligibility criteria
- 18 - 85 year old
- Have a clinical diagnosis of stable non-segmental vitiligo
- Depigmentation including at least 0.5% of the BSA on the face and neck
- Previously treated with topical tacrolimus 0.1% BD for at least 3 months without significant response
- Agree to stop using any topical treatments on face and neck and systemic treatment for vitiligo during the washout period until the trial concludes. Use of over-the-counter products approved by the investigator and...
- Both male and female patients must commit to using effective birth control to prevent pregnancy or fathering a child throughout the study
- people or their legally authorized representative, if applicable, must be able to understand and willing to provide informed consent at Screening visit
- Patients who refuse to give consent
- Presence of different vitiligo types or other skin depigmentation conditions like piebaldism or leprosy, etc.
- History of using depigmentation treatments other than hydroquinone for vitiligo or pigmentation issues
- Any skin condition affecting study participation, active skin infections one week before the study starts, issues impacting vitiligo evaluation, or serious health problems limiting involvement or increasing risk
- Significant medical disease that may hinder use of topical JAK inhibitor, e.g. serious infection, untreated chronic hepatitis, malignancy within 5 years except adequately treated non metastatic cancer, evidence of...
- Specific treatment use within certain periods before starting (Baseline visit): 1 week for topical vitiligo treatments 4 weeks for immunomodulators, photosensitizers, oral retinoids, methoxsalen, or live vaccines 8...
- Any prior application of topical or oral JAK inhibitors
- Hemoglobin under 10 g/dL, significant liver dysfunction, and/or evidence of HIV infection or positive for HIV antibodies at initial screening or current acquired, common variable or inherited, primary or secondary...
- Females of childbearing potential who are pregnant, during breastfeeding period, or those planning pregnancy during the study
- Those unlikely or unable to comply with the requirements of this study protocol
The study team makes the final eligibility decision.
Where it's taking place
- Hong Kong, Hong Kong
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 85 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hong Kong, Hong Kong. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.